HDFC Mid Cap Fund Direct Growth NAV at ₹217.7820 on 22 October; 5-Year Return at 16.74%

Key Takeaways

• HDFC Mid Cap Fund Direct Growth recorded an exact NAV of ₹217.7820 for 22 October 2026.
• Its five-year annualised return stood at 16.74%, while the latest 5paisa snapshot reported a three-year CAGR of 15.18%.
• The latest fund snapshot showed assets of ₹101,856 crore, an expense ratio of 0.76% and minimum SIP and lump-sum investments of ₹100 each.

HDFC Mid Cap Fund Direct Growth recorded a NAV of ₹217.7820 for 22 October 2026. The permitted Value Research Direct Plan record established the exact requested-date NAV after the refreshed 5paisa primary card remained at ₹217.78 for 21 October. Since an exact 22 October one-day percentage was not independently established, no daily movement has been stated.

Historical data showed a five-year annualised return of 16.74% as of 22 October. The latest 5paisa snapshot reported a three-year CAGR of 15.18% and a one-year trailing return of -1.03%. The difference across these periods reflects the different starting points used in each trailing-return calculation.

The scheme had a displayed fund size of ₹101,856 crore and a Direct Growth expense ratio of 0.76%. Both its minimum SIP and minimum lump-sum investment were ₹100. HDFC Mid Cap Fund is an equity scheme focused predominantly on mid-cap companies rather than a diversified all-market-cap mandate.

TREPS represented 8.37% in the latest 5paisa allocation display and must be treated as a short-term liquidity or money-market exposure, not as an equity holding. Among listed equities, Federal Bank was the largest disclosed position at 3.98%, followed by AU Small Finance Bank at 3.94%, Max Financial at 3.52% and Ipca Laboratories at 3.43%. Value Research also showed Glenmark Pharmaceuticals at 3.07% among the leading equity positions.

The presence of TREPS alongside equity holdings means concentration calculations should distinguish liquidity exposure from listed stocks. Historical return and risk statistics remain backward-looking measures rather than forecasts.